Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
Differential immunomodulation following checkpoint blockade in the orthotopic ID8-luc ovarian model
AACR 2023 -- The availability of syngeneic models for ovarian cancer is extremely limited. The ID8-luc ovarian model is established intraperitoneally with disease progression resulting in the accumulation of ascites fluid. However, solid tumors do not reliably form, making assessment of immunomodulation challenging. The ID8-luc model was originally developed to assess efficacy and has now been developed as a tool to investigate immuno-modulatory drug candidates by utilizing tissues in the peritoneal cavity of diseased animals for ex vivo analyses. Specifically, flow cytometry of diseased ovaries and ascites was employed to examine the effects of checkpoint inhibition on immune cells.